Understanding sex differences in neuroimaging biomarkers and clinical trials
Rachel F Buckley · 2025
Read Understanding sex differences in neuroimaging biomarkers and clinical trials by Rachel F Buckley (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11712831.txt.
Description
Rachel F Buckley argues that Alzheimer's trials must split their results by sex, because brain markers and drug effects differ between women and men. Modern trials use amyloid and tau scans to admit patients and to prove a drug worked. Some, including the lecanemab trial, hint that men and women respond differently. Women also progress faster once ill, especially with a known risk gene. Yet headline results are rarely broken out by sex. Her 2025 paper reviews five years of studies on sex differences in these imaging markers.
Blended averages can hide a drug that helps one sex and not the other. Buckley writes as a guide for trial designers and clinicians reading their results. The ask is simple: report the split. Her solo review gathers the marker evidence in one place. It is an argument about statistics with bedside consequences.
Catalog record
| CREATOR | Rachel F Buckley |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |